MONTREAL, May  07, 2025  (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that has assumed full commercial activities and is relaunching ONICIT® IV (palonosetron) in Brazil and Mexico, through its affiliates in those countries (United Medical Ltd. and Grupo Biotoscana de Especialidad S.A. de C.V., respectively).

In May 2022, Knight and Helsinn Healthcare SA ("Helsinn") had entered into an exclusive license, distribution and supply agreement for oral/IV AKYNZEO® (netupitant/palonosetron - fosnetupitant /palonosetron) in Canada, Brazil, Argentina, Uruguay and Paraguay, and ALOXI® oral/IV (palonosetron) in Canada. In January 2025, Knight and Helsinn announced that they expanded their existing relationship and entered into an exclusive license, distribution and supply agreement for ONICIT® IV (palonosetron) in Mexico, Brazil, and other LATAM countries. ONICIT® is marketed under the brand name ALOXI® in Canada.

ONICIT® solution for injection is approved and marketed in Brazil and Mexico for the prevention of acute nausea and vomiting associated with the initial and repeated cycles of moderately and highly emetogenic chemotherapy for cancer, and for the prevention of delayed nausea and vomiting associated with the initial and repeated cycles of moderately emetogenic chemotherapy for cancer in adults. In addition, ONICIT® is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults, for up to 24 hours after surgery. In Brazil, ONICIT® is also indicated for pediatric patients, from 1 month to 17 years of age, for the prevention of acute nausea and vomiting associated with the initial and repeated cycles of emetogenic chemotherapy for cancer, including highly emetogenic chemotherapy.

“We are proud to continue providing patients and health care professionals with advanced treatments like ONICIT® to help mitigate the debilitating effects of chemotherapy induced nausea and vomiting,” said Samira Sakhia, President and CEO of Knight. “ONICIT® is synergistic with our existing oncology portfolio and will continue leveraging the existing commercial and medical footprint.”

About ONICIT®

ONICIT® is a second generation 5-HT3 receptor antagonist with higher affinity for the 5-HT3 receptor compared to first-generation 5-HT3 receptor antagonists.1 A single dose of ONICIT® prior to chemotherapy provides protection over the entire overall phase (days 1–5) hence providing a simple and effective regimen. Efficacy was demonstrated both in the acute (day 1) and in the delayed (days 2-5) phase after chemotherapy.2,3

References

1 Rojas C, Slusher BS. Pharmacological mechanisms of 5-HT₃ and tachykinin NK₁ receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2012;684(1-3):1-7. doi:10.1016/j.ejphar.2012.01.046

2 Navari RM, Aapro M. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016;374(14):1356-1367. doi:10.1056/NEJMra1515442

3 Aapro MS. Palonosetron as an anti-emetic and anti-nausea agent in oncology. Ther Clin Risk Manag. 2007;3(6):1009-1020.

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.knighttx.com or www.sedarplus.ca.

About Helsinn

Helsinn is a global pharmaceutical company that builds, manufactures, launches, and commercializes products to improve the quality of life for patients with cancer and chronic disease, with a focus on supportive care, oncology and dermato-oncology. Helsinn, headquartered in Lugano, Switzerland, has direct commercial operations in the U.S. and a consolidated network of partners to reach out to patients in about 150 countries worldwide.

Established in 1976, Helsinn is a fourth-generation family-owned company with broad pharmaceutical and technical expertise. Helsinn is proud of its history of operating with great integrity, passion and quality. The company is committed to continuously striving for innovation for its patients and embracing sustainable growth as a core element of its strategic vision.

To learn more about Helsinn, please visit www.helsinn.com or follow us on LinkedIn and X.

Forward-Looking Statements

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2024, as filed on www.sedarplus.ca. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

Investor Contact: Knight Therapeutics Inc.  Samira Sakhia  Arvind UtchanahPresident & Chief Executive Officer Chief Financial OfficerT: 514.484.4483 T. +598.2626.2344F: 514.481.4116 Email: [email protected] Email: [email protected]: www.knighttx.com Website: www.knighttx.com